Drug Profile

HG 202

Alternative Names: HG-202

Latest Information Update: 06 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HuidaGene Therapeutics
Class Eye disorder therapies; Gene therapies
Mechanism of Action RNA modulators; Vascular endothelial growth factor A expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Nov 2024 US FDA approves IND application for HG 202 in Age-related macular degeneration
02 Oct 2024 HuidaGene Therapeutics plans a phase I BRIGHT trial for Age related macular degeneration in Unknown location (Subretinal, Injection) (NCT06623279)
15 Sep 2023 Preclinical trials in Age-related macular degeneration in China (Subretinal) (NCT06031727)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com